M
Michael A. Moses
Researcher at Clarkson University
Publications - 9
Citations - 511
Michael A. Moses is an academic researcher from Clarkson University. The author has contributed to research in topics: Chaperone (protein) & Cancer cell. The author has an hindex of 9, co-authored 9 publications receiving 351 citations. Previous affiliations of Michael A. Moses include University of Rochester Medical Center.
Papers
More filters
Journal ArticleDOI
Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
Michael A. Moses,Yeong Sang Kim,Genesis M. Rivera-Marquez,Nobu Oshima,Matthew J. Watson,Kristin Beebe,Catherine Wells,Sunmin Lee,Abbey D. Zuehlke,Hao Shao,William E. Bingman,Vineet Kumar,Sanjay V. Malhotra,Nancy L. Weigel,Jason E. Gestwicki,Jane B. Trepel,Leonard M. Neckers +16 more
TL;DR: Data reveal that, in addition to recognized roles of Hsp40 and Hsp70 in FL-AR LBD remodeling, ARv lacking the LBD remain dependent on molecular chaperones for stability and function.
Journal ArticleDOI
Heat shock protein 90: its inhibition and function
TL;DR: The molecular chaperone heat shock protein 90 (Hsp90) facilitates metastable protein maturation, stabilization of aggregation-prone proteins, quality control of misfolded proteins and assists in keeping proteins in activation-competent conformations.
Journal ArticleDOI
Exploration of Benzothiazole Rhodacyanines as Allosteric Inhibitors of Protein–Protein Interactions with Heat Shock Protein 70 (Hsp70)
Hao Shao,Xiaokai Li,Michael A. Moses,Luke A. Gilbert,Chakrapani Kalyanaraman,Zapporah T. Young,Margarita Chernova,Sara N. Journey,Jonathan S. Weissman,Byron Hann,Matthew P. Jacobson,Len Neckers,Jason E. Gestwicki +12 more
TL;DR: The hypothesis that Hsp70 may be a promising target for anticancer therapeutics is supported through structure- and property-based design of ∼300 analogs and JG-231 was found to reduce tumor burden in an MDA-MB-231 xenograft model.
Journal ArticleDOI
Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric Ligands.
Sara Sattin,Jiahui Tao,Gerolamo Vettoretti,Elisabetta Moroni,Marzia Pennati,Alessia Lopergolo,Laura Morelli,Antonella Bugatti,Abbey D. Zuehlke,Michael A. Moses,Thomas Prince,Toshiki Kijima,Kristin Beebe,Marco Rusnati,Len Neckers,Nadia Zaffaroni,David A. Agard,Anna Bernardi,Giorgio Colombo +18 more
TL;DR: Analysis of protein responses to first-generation activators was exploited to guide the design of novel derivatives with improved ability to stimulate ATP hydrolysis and act as allosteric activators of the chaperone and affect the viability of cancer cell lines for which proper functioning of Hsp90 is necessary.
Journal ArticleDOI
Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy.
Nobu Oshima,Ryo Ishida,Shun Kishimoto,Kristin Beebe,Jeffrey R. Brender,Kazutoshi Yamamoto,Daniel J. Urban,Ganesha Rai,Michelle S. Johnson,Gloria A. Benavides,Giuseppe L. Squadrito,Dan Crooks,Joseph Jackson,Abhinav Joshi,Bryan T. Mott,Jonathan H. Shrimp,Michael A. Moses,Min-Jung Lee,Akira Yuno,Tobie D. Lee,Xin Hu,Tamara Anderson,Donna F. Kusewitt,Helen H. Hathaway,Ajit Jadhav,Didier Picard,Jane B. Trepel,James Mitchell,Gordon M. Stott,William J. Moore,Anton Simeonov,Larry A. Sklar,Jeffrey P. Norenberg,W. Marston Linehan,David J. Maloney,Chi V. Dang,Chi V. Dang,Alex G. Waterson,Matthew D. Hall,Victor M. Darley-Usmar,Murali Krishna,Leonard M. Neckers +41 more
TL;DR: Using hyperpolarized magnetic resonance spectroscopic imaging (HP-MRSI), in vivo LDH inhibition is demonstrated in two glycolytic cancer models, MIA PaCa-2 and HT29, and the depth and duration are correlated with direct anti-tumor activity.